Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | One to watch: KEYNOTE-866, perioperative pembro with neoadjuvant chemo in MIBC

Arlene Siefker-Radtke • 28 Sep 2019
ESMO 2019
Bladder Cancer Genitourinary Cancer Checkpoint Inhibitors Pembrolizumab
KEYNOTE-866

Speaking from the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain, Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the ongoing phase 3 KEYNOTE-866 study (NCT03924856). This trial is investigating perioperative pembrolizumab in combination with neoadjuvant chemotherapy in cisplatin-eligible patients wth muscle-invasive bladder cancer.

More from Arlene Siefker-Radtke

Current limitations and research on molecular subtyping in the treatment of urothelial carcinoma
1:11
Current limitations and research on molecular subtyping in the treatment of urothelial carcinoma
Arlene Siefker-Radtke • 31 May 2024
THOR: impact of FGFR3 alterations in mUC on subtype and outcomes with erdafitinib vs pembrolizumab
1:49
THOR: impact of FGFR3 alterations in mUC on subtype and outcomes with erdafitinib vs pembrolizumab
Arlene Siefker-Radtke • 31 May 2024
The role of enfortumab vedotin in urothelial cancer treatment
1:18
The role of enfortumab vedotin in urothelial cancer treatment
Arlene Siefker-Radtke • 31 May 2024
Phase III TROPICS-04 trial: sacituzumab govitecan vs treatment of choice in advanced mUC
1:13
Phase III TROPICS-04 trial: sacituzumab govitecan vs treatment of choice in advanced mUC
Arlene Siefker-Radtke • 31 May 2024

Related Videos

Real-world outcomes highlight unmet needs in R/R germ cell tumors
1:26
Real-world outcomes highlight unmet needs in R/R germ cell tumors
Darren Feldman • 24 Oct 2026
The future of targeting claudin-6 in relapsed germ cell tumors
0:52
The future of targeting claudin-6 in relapsed germ cell tumors
Darren Feldman • 24 Oct 2026
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
2:18
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
Darren Feldman • 24 Oct 2026
How will EIK1003 fit in the treatment landscape of prostate cancer?
0:42
How will EIK1003 fit in the treatment landscape of prostate cancer?
Guru Sonpavde • 24 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals